Treatment of lymphatic disease is complicated and controversial, due in part to the limited understanding of the lymphatic system. Lymphedema (LE) is a frequent complication after surgical resection and radiation treatment in cancer survivors, and is especially debilitating in regions where treatment options are limited. Although some extremity LE can be effectively treated with manual lymphatic drainage (MLD) therapy or compression devices to direct proximal lymph transport, head and neck LE is more challenging, due to complicated geometry and complex lymphatic structure in head and neck region.
INTRODUCTION
Lymphedema (LE) commonly results from irradiation and/or surgical excision of lymph nodes for cancer treatment. It usually occurs in upper or lower extremities on survivors of breast, melanoma, cervical, endometrial, vulvar, prostate, penile, and soft tissue cancers [1] . Onset of LE could be days to years after the initial insult of lymphatics. LE is incurable and may be the most extreme of all chronic lymphatic conditions manifested by irresolvable edema. When not well managed, the disease most likely progresses to fibrosis, pain/paresthesias, extreme disfigurement, and reduced immune surveillance [2] . The accepted method to manage LE in upper and lower extremities is through complete decongestive therapy (CDT), which includes manual lymphatic drainage (MLD), compression bandaging, therapeutic exercise, and meticulous skin care. Pneumatic compression devices (PCDs) can also be used as part of physical therapy for in CDT. Therapeutic efficacy on extremity is typically measured by change in limb volume estimated from circumferential limb measurements or limb water displacement. Unfortunately, when LE involves anatomic regions other than the extremities, such as the cervical and facial areas as in the case of head and neck cancer survivors, conventional measurements of tissue volume reduction are difficult, and lymphatic architecture in the affected areas vary greatly between patients [3] , thus presenting difficulties for efficient management. Currently, the diagnosis of LE mainly relies on the volume change of the affected area to indicate the presence of clinically measurable lymphedema. There are no routine imaging modalities readily available to simultaneously image the structure and function lymphatic vessels. Direct lymphangiography has been one gold standard but infrequently used approach to image lymphatics. It involves cannulation of an oil-soluble contrast agent into a distal lymphatic vessel after an incision made in the skin to allow for exposure and manipulation of a lymphatic vessel. This technique may pose a risk of worsening LE in part due to the disruption of the already impaired lymphatics and in part because of the high osmolarity of the contrast agent. An alternative method, indirect lymphangiography, which consists of the acquisition of X-ray or magnetic resonance images after intradermal injection of a water-soluble contrast agent, is less invasive. This technique does not require the dissection or cannulation of the lymphatic vessel, but it requires intradermal administration of substantial volumes of contrast agent that is not currently available in the US. Nuclear lymphoscintigraphy is commonly used for diagnosis of lymphatic transport dysfunction. However, insufficient spatial and temporal resolution sometimes limits the accurate examination of lymphatic anatomy and function. Better understanding of the lymphatics in disease is important for successful treatment of LE. Recently, we developed an investigational technique involving near-infrared (NIR) fluorescence imaging of the lymphatics. With small volumes and microdosages of indocyanine green (ICG), it allowed us to simultaneously study the lymphatic architecture and function in normal control human subjects and patients with extremity LE [4] , and their response to MLD [5] and PCD [6] . This technique has not been used previously to study lymphatic in head and neck LE. Herein, we present a case using NIR fluorescence imaging to map the lymphatic drainage of a patient suffering from head and neck LE, and using longitudinal profilometry to assess to the efficacy of treatment.
MATERIALS AND METHODS

Study Design
The protocol used for this compassionate use study was approved under single patient combinational investigational new drug application (IND 105,824) for the off-label use of ICG as a NIR fluorescent contrast agent. The HIPPA-compliant study was approved by the Institutional Review Boards (IRBs) at the University of Texas Health Science Center and Memorial Hermann Hospital, where the study was conducted. A 50-year-old African-American male subject was recruited for imaging in July 2009, and he has since provided permission for his medical history and images to be presented herein. He was referred by an oncology clinic to the Memorial Hermann Center for Lymphedema Management for his LE as subsequence of hemimandibulectomy and hemiglossectomy, radiation and chemotherapy in 2005 and 2008 for oral cancer. He developed radiation fibrosis of the neck with significant facial edema. His LE involved the eyelids, tongue, face, and cheeks. The facial edema was minimally reduced by MLD, but intraoral swelling was not improved. Surgical scars and fibrosis appeared to obstruct most expected lymphatic outflow tracts from his face. We sought to map lymphatic structure in his face and neck using NIR fluorescence imaging to direct MLD therapy by moving lymph toward patent channels, and thus further reduce the edema.
Near-infrared fluorescence imaging and profilometry
Immediately after four intradermal injections of ICG of 25 µg in 0.1 cc each (demarked as injections (1) through (4) in Figure 1 ), NIR fluorescence images were acquired on the head and neck using a custom-built fluorescence imaging system described elsewhere [4] . In brief, the system consisted of an excitation light source (785 nm), holographic and band-pass filters (830 nm), a NIR sensitive image intensifier, and a customized CCD camera. Sequential fluorescence images were acquired using a 200 msec camera integration time permitting near real time imaging of the lymphatics. Five subsequent injections at sites (5) through (9) occurred approximately 1.5 hours later. Injection sites were covered with black vinyl tape to avoid oversaturation of the camera system by bolus of ICG. The subject wore eye protection against the unlikely event of damage from the <1.9 mW/cm 2 laser diode illumination. MLD using the technique developed by Vodder [7] was performed 60 minutes after the start of imaging by a certified LE therapist during the imaging sections; neither oils nor lotions were used during MLD therapy. Following NIR imaging, profilometry was performed using a commercial camera system (3dMDface™ System -3dMD LLC, Atlanta, GA) to obtain threedimensional (3D) color facial surface images. The head and neck region of the subject was illuminated with patterned light and imaged using two camera pods. The 3D image provided a precise roadmap of the facial structure and scar around the neck (marked with dashed lines in Figure 1 ). In the four subsequent weeks as part of regular standard of care, 3D images were used to document the change in tissue volumes on the face to track therapeutic efficacy. No adverse events were associated with the imaging agent or devices. Owing to the advanced stage of LE, the subject was unable to open his mouth wide enough for imaging lymphatics within the oral cavity. (1) and (2), also not shown, injection sites (7) and (8) 
RESULTS AND DISCUSSION
Architecture and flow of lymphatics in head and neck
NIR fluorescence images obtained from the head and neck region allowed the in vivo visualization of lymphatic structures. Figure 2 shows a tortuous lymphatic channel traversing across the midline and connecting lymph basins on the right and left sides of the neck. This vessel may have formed through the process of lymphangiogenesis after the obstruction or damage of preexisting lymphatics due to the surgery and irradiation. The direction of lymph transport could not be identified as the imaging was not conducted during the administration of contrast agent. This unique lymphatic structure is interesting. It could be crucial if found on normal subjects since it has been traditionally believed that lymphatic drainage is within strictly demarcated watersheds delineated by an imaginary horizontal plane at the level of the umbilicus and crossed by the midsagittal plane vertically. However, we were able to demonstrate lymphatic drainage crossing from one watershed on one side into another on the contralateral side. This finding would support the frequently argued hypothesis that directing lymph transport across the midline during MLD is possible. Demonstration of the typically unexpected drainage pattern in diseased lymphatics might imply a different strategy in the staging of cancer because cancer cells could migrate directly into the contralateral lymphatic basin which is not normally anticipated. Figure 3 shows the lymphatic structure on the right side of the subject's face and neck. Similar to what has be demonstrated in the limbs of normal subjects and some LE subjects [4] , propulsive lymphatic flow was observed in a lymphatic channel draining from the injection site (5) below the eye toward the ear (refer to supplement video 1). Dense capillary networks and extravascular accumulation of ICG, similar abnormal pattern seen in limbs of some LE subjects, were also seen in the region between ear and upper neck. There are well-defined but tortuous lymphatic channels seen crossing the line of the surgical incision on the neck and draining to the jugular notch. This is also a unique finding that could change MLD techniques. Since it has been taught as a dogma that lymph vessels do not cross scars, an attempt to drain accumulated lymph across a scar has been deemed unproductive for decongestion of a lymphedematous area. Our results suggest the dogma to be incorrect and that MLD across scars could be beneficial. Unfortunately, similar imaging on the head and neck of normal subjects has not been conducted, thus no comparison to normal lymphatic architecture and contractile function could be made. Figure 4 shows the lymphatic structure on the left side of the face and neck. A lymphatic channel draining lymph from the injection site (7) below the eye toward the neck was observed. Propulsive lymph flow was recorded in a channel draining from the injection site (3) toward ear (refer to supplement video 2). Extravascular accumulation of ICG was seen between injection site (4) and the neck as shown in Figure 5 and an ICG laden cervical node was identified. The lack of symmetric lymphatic architecture compared to the contralateral side or functioning lymphatics may have resulted from the process of lymphangiogenesis or co-opting of otherwise non-functional lymph channels in response to the impairment of preexisting lymphatic vessels. Longitudinal imaging studies following lymphatic obstruction of surgery and radiation therapy would be necessary to understand the etiology of the lymphatic architecture and function.
Prior to the NIR fluorescence imaging observation, lymph flow from this subject's face was assumed to drain toward the back of the neck and then toward the axilla because of the disruption owing to surgery and radiation therapy in the front of the neck. Figure 6 shows the frontal view of the lymphatic structure in the cervical region as well as extravascular accumulation of ICG at the chin and right side of the upper neck, and in a smaller area on the left side of the upper neck. Below the incision line, several well-defined channels near jugular notch were also observed, suggesting that drainage across the scars did occur in cervical regions. No fluorescence was visualized in the axilla by 3 hours after ICG injection on face, suggesting that drainage from the injection sites occurred primarily in the cervical regions during this time (Figure 7) . Consequently, the mapping of functional lymphatic vessels in cervical region provides guidance for MLD therapy to move fluid toward these functioning vessels, and cervical as well as subclavian lymph nodes. 
Longitudinal assessment of edema
Results of longitudinal assessment of edema using profilometry on the face are illustrated in Figure 8 . By taking a difference of the tissue surface maps, an increase in swelling is denoted by a positive difference (rendered in magenta color) while a reduction is indicated by a negative distance (rendered by green color). Increased swelling in the cheek from week 1 to week 2 was seen, but there was subsequently decrease in week 3 possibly owing to effective therapy using NIR fluorescence imaging as guidance. The swelling was regained in the cheek in week 4 due to the relapse of metastatic disease within subject's oral cavity. 
CONCLUSION
Herein, we present a compassionate use case of NIR fluorescence imaging to map functioning lymphatic vessels for directing efficient MLD therapy in the head and neck LE. Unfortunately, the subject suffered severe recurrence of cancer, eliminating the possibility of long-term follow-up. Nonetheless, we demonstrated the ability of NIR fluorescence imaging to track functional vessels in order to direct therapy. Although newly recruited lymphatic vessels following obstruction could not be identified in the single imaging session, we were able to longitudinally track changes in edema using surface profilometry. Given the small dose of ICG employed and its normally rapid clearance from the body, repeated dosing for multiple NIR fluorescence imaging sessions longitudinally could be used to track progress in improvement of contractile lymphatic activity and recruitment of new vessels. However, further lymphatic imaging studies with normal and diseased subjects are needed to evaluate the reproducibility and incidence of the findings that we describe here.
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